Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of
Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not
arising on the face or scalp